Flamel Technologies S.A. (ADR) (NASDAQ:FLML) Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate. Flamel Technologies S.A. (ADR) (NASDAQ:FLML) shares after opening at $13.75 moved to $14.75 on last trade day and at the end of the day closed at $14.45. Company price to sales ratio in past twelve months was calculated as 15.59 and price to cash ratio as 39.57. Flamel Technologies S.A. (ADR) (NASDAQ:FLML) showed a positive weekly performance of 11.15%.
Leerink Swann reiterated their outperform rating on shares of Alkermes Plc (NASDAQ:ALKS) in a research report sent to investors on Tuesday morning, Analyst Ratings Network reports. The firm currently has a $66.00 price target on the stock. Alkermes Plc (NASDAQ:ALKS) shares advanced 7.53% in last trading session and ended the day on $45.25. ALKS return on equity ratio is recorded as 2.10% and its return on assets is 1.40%. Alkermes Plc (NASDAQ:ALKS) yearly performance is 90.13%.
Ambit Biosciences Corporation (NASDAQ:AMBI) announced that it has commenced a phase III study (QUANTUM-R) on its lead oncology candidate, quizartinib. Quizartinib is a once-daily, orally administered FMS-like tyrosine kinase-3 (FLT3) inhibitor. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares moved up 6.00% in last trading session and was closed at $5.83, while trading in range of $5.42 – $5.89. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) year to date (YTD) performance is -8.76%.
Valeant Pharmaceuticals International Inc. (NYSE:VRX), Canada’s most acquisitive and indebted junk-rated company, will probably turn to the equity market to fund further purchases as it seeks to avoid a credit-rating cut. Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) weekly performance is -3.25%. On last trading day company shares ended up $129.34. Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) distance from 50-day simple moving average (SMA50) is -6.13%. Analysts mean target price for the company is $52.38.
Leave a Reply